The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by DRP – data published at ASCO
Hoersholm, Denmark, May 17th, 2017 – Oncology Venture Sweden AB (“Oncology Venture”) today announced that the previously warranted abstract with DRP data for epirubicin for breast cancer has been published electronically on the website of ASCO (American Society of Clinical Oncology). The title of the abstract is “Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort”. The DRP was significantly associated to Progression Free Survival (PFS) in a cohort of 137 metastatic breast cancer patients. PFS is a measure of the total time epirubicin can block tumor growth. The estimated median time to progression for a patient with a DRP value of 25% was 7 months versus 13 months for a patient with a DRP value of 75%.
The poster including update of data will be presented on the 4th of June 2017 at the annual ASCO conference in Chicago, USA taking place from June 2-6 2017.
benefit with a reduction in their tumor size. Until now there has been no method to find out who will benefit and who will not. The current study looked at 137 epirubicin treatments to evaluate Medical Prognosis Institutes Epirubicin Drug Response Predictor (DRP™) in-licensed by Oncology Venture. The DRP was significantly associated to Progression Free Survival (PFS). PFS is a measure of the total time epirubicin can block tumor growth. The estimated median time to progression for a patient with a DRP value of 25% was 7 months versus 13 months for a patient with a DRP value of 75%.
The result is also of tremendous value to MPI as epirubicin response prediction is an important part of building a broader Personalized Response Prediction Compass for individual patients and for Oncology Ventures spinout 2X Oncology Inc. in developing the GSH-liposomal- doxorubicin for breast and brain cancer with our in-licensed product 2X-111.
The abstract will be released by ASCO
on May 17, 2017, at 5:00 PM EDT/23:00 CET on abstracts.asco.org
An up-date on data from the abstract will be presented as a poster on the poster session Breast Cancer—Metastatic
on the 4th of June 2017 at 8:00 AM-11:30 AM local time/15:00-18:30 CET.
“This is very good news, our patented Epirubicin DRP is now also validated in clinical practice and I am confident that we can use this strong tool to successfully develop our product 2X-111 in breast and hopefully also in brain cancer and also strengthen MPI’s response compass. I look forward to the presentation of the epirubicin DRP™ data at the annual ASCO – the largest event for anticancer drug developers”, said Adjunct Professor Peter Buhl Jensen, M.D., CEO of Oncology Venture. “2X-111 will be developed in two focused Phase 2 trials in metastatic Breast Cancer and in Glioblastoma in 2X Oncology Inc. a precision medicines company for Women’s Cancers – a spinout from Oncology Venture currently 92% owned by Oncology Venture,” Peter Buhl Jensen further commented.
ASCO, American Society of Clinical Oncology, ANNUAL MEETING. McCormick Place, Chicago, Illinois, USA.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. The ASCO Annual Meeting is considered the premiere international forum for the presentation of scientific research and state-of-the-art education in clinical oncology. The five-day event attracts 30,000 attendees from around the world. Clinical trial results and updates presented at ASCO's Annual Meeting represent the significant progress made each year in the fight against cancer.
For further information on Oncology Venture please contact
|Ulla Hald Buhl , COO and Chief IR & CommunicationsMobile: +45 2170 1049E-mail: firstname.lastname@example.org||or||Peter Buhl Jensen , CEOMobile: +45 21 60 89 22E-mail: email@example.com|
This information is that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 17th 2017.
About the DRP™ Companion Diagnostic
Developed by and in-licensed from Medical Prognosis Institute, the DRP™ screening platform utilizes messenger RNA (mRNA) gene expression signatures from patient biopsies to identify patients with a high likelihood of responding to specific cancer-fighting therapies. This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines, combined with clinical tumor biology and clinical correlates in a systems biology network. Specific DRP™’s are developed for each pipeline product, which will enable us to identify and predict which patients are most likely to respond and thereby benefit from a given pipeline product. This would enable likely responders to receive appropriate treatment while expediting the decision path for predicted non-responders, saving them critical time and money in their cancer fight.
About Oncology Venture Sweden AB (OV)
OV is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out 2X Oncology Inc. a company focused on developing precision medicine for women’s cancer with three anticancer products in pipeline and OV-SPV2 which will test and potentially develop an oral Tyrosine Kinase inhibitor from a Big Pharma the treatment of cancers.